Loading...
•
Dec 31, 2023
Esperion Q4 2023 Earnings Report
Esperion's Q4 2023 financial results were reported, showcasing significant revenue growth and strategic advancements.
Key Takeaways
Esperion reported a 72% increase in Q4 total revenue, driven by U.S. net product revenue growth of 39% and collaboration revenue growth of 195%. The company also resolved litigation with DSE, securing $100 million and potential cost savings. They are preparing for potential cardiovascular risk reduction label approvals from the FDA and EMA.
Total revenue increased by 72% year-over-year to $32.3 million.
U.S. net product revenue grew by 39% year-over-year to $20.8 million.
Collaboration revenue increased by 195% year-over-year to $11.5 million.
Retail prescription equivalents grew 44% year-over-year and 8% quarter-over-quarter.
Revenue by Segment
Forward Guidance
The company expects full year 2024 operating expenses to be approximately $225 million to $245 million, including $20 million in non-cash expenses related to stock compensation.
Revenue & Expenses
Visualization of income flow from segment revenue to net income
Historical Earnings Impact
Analyze how earnings announcements historically affect stock price performance
Avg. Return Before/After Earnings
Loading earnings performance data...
Loading earnings reaction data...